<DOC>
	<DOCNO>NCT01957059</DOCNO>
	<brief_summary>The purpose study see whether BMN053 safe effective use medication Duchenne muscular dystrophy ( DMD ) patient mutation around location 53 DNA dystrophin protein .</brief_summary>
	<brief_title>A Phase I/II Study BMN053 Subjects With Duchenne Muscular Dystrophy ( DMD )</brief_title>
	<detailed_description>A Phase I/II , open-label , dose escalate 48-week treatment study assess safety tolerability , pharmacokinetics , pharmacodynamics efficacy BMN 053 ( previously know PRO053 ) subject Duchenne muscular dystrophy</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>1 . Duchenne muscular dystrophy result mutation correctable treatment BMN053 confirm stateoftheart DNA diagnostic technique cover DMD gene exon , include limited MLPA ( Multiplex Ligationdependent Probe Amplification ) , CGH ( Comparative Genomic Hybridisation ) , SCAIP ( Single Condition Amplification/Internal Primer ) HRMCA ( HighResolution Melting Curve Analysis ) . 2 . Ambulant boy age least 5 year day first dose able walk least 300 metre 6 minute walk distance ( 6MWD ) test . In addition , result 6MWD test must within Â±30 metres 2 3 pretreatment visit ( screen 1 , 2 baseline ) prior first BMN053 administration . 3 . Adequate quality biopsy ( confirm MRI ) lateral head gastrocnemius muscle . Only exceptional circumstance alternative muscle ( preferably brachii ) consider biopsy follow discussion Principal Investigator BioMarin Medical Monitor . 4 . Life expectancy least 3 year inclusion study . 5 . Glucocorticosteroid use stable least 3 month prior first BMN053 administration . Subjects must receive glucocorticosteroids least 6 month prior first BMN053 administration . 6 . Willing able adhere study visit schedule protocol requirement . 7 . Written inform consent sign ( parent ( ) /legal guardian and/or subject , accord local regulation ) . 8 . In France , subject eligible inclusion study either affiliate , beneficiary , social security category . 9 . Anticipated adequate vein access intravenous ( IV ) infusion . 1 . Current history liver disease impairment . 2 . Current history renal disease impairment . 3 . At least two aPTT upper limit normal ( ULN ) within last month prior first dose BMN053 . 4 . Screening platelet count lower limit normal ( LLN ) . 5 . Acute illness within 4 week prior first dose BMN053 may interfere study assessment . 6 . Severe mental retardation and/or behavioural problem , opinion Investigator , prohibit participation study . 7 . Severe cardiomyopathy , opinion Investigator prohibit participation study . If subject leave ventricular ejection fraction &lt; 45 % screening , Investigator discus inclusion subject Medical Monitor . 8 . Expected need daytime mechanical ventilation within next year . 9 . Use anticoagulant , antithrombotics antiplatelet agent . 10 . Use idebenone form coenzyme Q10 within 1 month prior start screen study . 11 . Use nutritional herbal supplement , opinion Investigator , may influence muscle performance within 1 month prior first dose BMN053 . 12 . Use investigational product participation another trial investigational product , within 6 month prior start screen study .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>DMD</keyword>
	<keyword>Duchenne muscular dystrophy</keyword>
	<keyword>Duchenne</keyword>
	<keyword>BMN053</keyword>
	<keyword>BioMarin</keyword>
</DOC>